Antibody

Altamira Therapeutics Announces Collaboration with Univercells Group on Nanoparticle-Delivered mRNA Vaccines

Retrieved on: 
Monday, March 25, 2024
Semaphore, Cell, Patient, RNA, Messenger, Doctor of Philosophy, Infection, Antibody, Therapy, Vaccine

Altamira Therapeutics Ltd. (“Altamira” or the “Company”) (Nasdaq:CYTO), a company providing nanoparticle-based technology for efficient RNA delivery to extrahepatic targets, today announced that it has entered into a collaboration agreement with Univercells Group (“Univercells”) to evaluate the use of the Company’s proprietary SemaPhore platform for the delivery of mRNA vaccines.

Key Points: 
  • Altamira Therapeutics Ltd. (“Altamira” or the “Company”) (Nasdaq:CYTO), a company providing nanoparticle-based technology for efficient RNA delivery to extrahepatic targets, today announced that it has entered into a collaboration agreement with Univercells Group (“Univercells”) to evaluate the use of the Company’s proprietary SemaPhore platform for the delivery of mRNA vaccines.
  • Univercells is a global life sciences company creating platforms for developing and manufacturing biologics, including mRNA vaccines and therapeutics, in a simple, scalable and cost-efficient way.
  • Should the experiments prove successful, Univercells and Altamira intend to discuss and negotiate a commercial agreement for the development and manufacturing of nanoparticle-based mRNA vaccines using Univercells’ production platform.
  • “We are thrilled to initiate this collaboration with Univercells to explore SemaPhore as a delivery vehicle for mRNA vaccines”, commented Covadonga Pañeda, PhD, Altamira’s Chief Operating Officer.

Invivyd Announces FDA Authorization for Emergency Use of PEMGARDA™ (Formerly VYD222) for Pre-exposure Prophylaxis (PrEP) of COVID-19

Retrieved on: 
Friday, March 22, 2024
Diphenhydramine, Anaphylaxis, Hook effect, Pre-exposure prophylaxis, Half-life, Risk, Bone marrow, COVID-19, Patient, Metoprolol, Adrenaline, Epitope, DSM-IV codes, SARS-CoV-2, Death, Adolescence, Bank statement, Post-exposure prophylaxis, Clinical trial, CDC, Antibody, Vaccination, Safety, Immunodeficiency, Vaccine, FDA, Food, Medicine

Recipients should not be currently infected with or have had a known recent exposure to an individual infected with SARS-CoV-2.

Key Points: 
  • Recipients should not be currently infected with or have had a known recent exposure to an individual infected with SARS-CoV-2.
  • “The PEMGARDA EUA marks a transformational moment for Invivyd and for the many moderately to severely immunocompromised people who are vulnerable to COVID-19 disease in the U.S.
  • It was developed using INVYMAB™, the company’s platform approach which combines state-of-the-art viral surveillance and predictive modeling with advanced antibody engineering.
  • The severity of the reactions was generally mild (17/27) or moderate (8/27), but two reactions were life-threatening.

HOOKIPA Pharma Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights

Retrieved on: 
Friday, March 22, 2024
SIV, Clinical trial, Hepatitis, Head, CPI, Serum, Hepatitis B, Partnership, HIV, Oncology, Gilead Sciences, Patient, Lung, Journal, Viral load, Pembrolizumab, HBV, Trial of the century, IND, Infection, Hepatocyte, Arenavirus, Antibody, Vaccination, Intellectual property, FDA, Liver, Animal, Pharmaceutical industry

“It was a defining year for HOOKIPA as we witnessed the powerful potential of our novel arenaviral immunotherapies in action.

Key Points: 
  • “It was a defining year for HOOKIPA as we witnessed the powerful potential of our novel arenaviral immunotherapies in action.
  • Data was initially presented in May 2023 and additional patient data was provided in October at the European Society for Medical Oncology Congress 2023.
  • HOOKIPA expects to initiate a Phase 1 clinical study of HB-500 in people with HIV in the second quarter of 2024.
  • In June 2023, the Company completed a $50.0 million public offering of common stock and non-voting convertible preferred stock.

Virginia Milk Bank Seeks Donors for Hospitalized Babies

Retrieved on: 
Wednesday, March 20, 2024
Breast milk, Jaundice, Retinopathy, Nutrient, Lactation, Disease, Memory, Short bowel syndrome, CHKD, Risk, Necrotizing enterocolitis, Hospital, Milk, American Academy, Infant, Death, NICU, Life, Protein, Kidney disease, Intraparenchymal hemorrhage, Woman, Holiday, Antibody, Oxygen, Premature, Paratriathlon, Charli, ROP, Pediatrics (journal), Pediatrics, Dairy

Knowing that her breast milk was the best nutrition for Charli, Moultrie tried pumping to get her milk supply started.

Key Points: 
  • Knowing that her breast milk was the best nutrition for Charli, Moultrie tried pumping to get her milk supply started.
  • After two weeks of consistently pumping with scant results, Moultrie was grateful to learn that Charli could receive safe, pasteurized human milk through the hospital's donor milk bank.
  • The milk bank also has a legacy program for women who have lost a baby but want to donate their milk to help other infants.
  • “But there are times around the holidays and during the summer when we only have enough milk for hospitalized babies.”
    This means the milk bank is not always able to provide milk to babies who have been discharged from the hospital with a doctor’s prescription for pasteurized donor human milk.

Tenaya Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Retrieved on: 
Monday, March 18, 2024
PKP2, Biopsy, ARV, Administration, Fast track (FDA), Gene editing, Patient, SAN, CGMP, BlackRock, HDAC6, Column, G&A, IND, Research and development, Clinical trial, HCM, Investment, Therapy, Antibody, MYBPC3, Safety, FDA, ARVC, Heart failure, LP, Pharmaceutical industry

SOUTH SAN FRANCISCO, Calif., March 18, 2024 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today reported financial results for the fourth quarter and full year ended December 31, 2023, and provided a corporate update.

Key Points: 
  • “Tenaya had a successful year of sustained execution in 2023 that meaningfully advanced our portfolio of genetic medicines for heart disease.
  • Research & Development (R&D) Expenses: R&D expenses were $22.9 million for the fourth quarter and $98.0 million for the full year ended December 31, 2023.
  • General & Administrative (G&A) Expenses: G&A expenses were $8.6 million for the fourth quarter and $33.2 million for the full year ended December 31, 2023.
  • Net Loss: Net loss was $29.9 million, or $0.40 per share for the fourth quarter ended December 31, 2023.

Sino Biological Announces Services Partnership with Rapid Novor

Retrieved on: 
Thursday, March 14, 2024
ChiNext, Drug discovery, Partnership, Research, Protein, Antibody, De novo, Vaccine

BEIJING, China, March 14, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire — Sino Biological, Inc. (“Sino Biological” or the “Company”), a biotechnology company listed on the Shenzhen stock exchange subsidiary ChiNext (SZSE: 301047), which provides biological research reagents and related technical contract research services, is pleased to announce the formation of a services partnership with Toronto, Canada-based Rapid Novor, Inc. (“Rapid Novor”).  Under the terms of this agreement, Sino Biological will market Rapid Novor’s proprietary de novo REmAb monoclonal antibody (mAb) sequencing service in combination with its custom mAb development and production services.  Geographic areas covered under this partnership include China, Singapore, Thailand, Malaysia, Indonesia, Vietnam, Philippines, Japan and South Korea.

Key Points: 
  • BEIJING, China, March 14, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire — Sino Biological, Inc. (“Sino Biological” or the “Company”), a biotechnology company listed on the Shenzhen stock exchange subsidiary ChiNext (SZSE: 301047), which provides biological research reagents and related technical contract research services , is pleased to announce the formation of a services partnership with Toronto, Canada-based Rapid Novor, Inc. (“Rapid Novor”).
  • Under the terms of this agreement, Sino Biological will market Rapid Novor’s proprietary de novo REmAb monoclonal antibody (mAb) sequencing service in combination with its custom mAb development and production services.
  • Headquartered in Beijing, China, Sino Biological is the world’s leading provider of mammalian cell-based recombinant proteins, antibodies, and related contract research services.
  • Rob Burgess, Sino Biological’s Chief Business Officer, stated, “Rapid Novor’s REmAb monoclonal antibody sequencing capabilities perfectly complement Sino Biological’s antibody development and manufacturing services.

Vaxart Provides Business Update and Reports Full Year 2023 Financial Results

Retrieved on: 
Thursday, March 14, 2024
Mother, Research, Breast milk, Conference call, Development, Bill, Webcast, COVID-19, SAN, VOC, GI, Messenger, XBB, NHP, SARS-CoV-2, Insurance, Investment, Clinical trial, Antibody, Safety, Vaxart, Nextgen, Vaccine, FDA, Food, Pharmaceutical industry

SOUTH SAN FRANCISCO, Calif., March 14, 2024 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today announced its business update and financial results for the full year 2023.

Key Points: 
  • ET
    SOUTH SAN FRANCISCO, Calif., March 14, 2024 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today announced its business update and financial results for the full year 2023.
  • Financial Results for the Full Year Ended December 31, 2023
    Cash, cash equivalents and investments totaled $39.7 million as of December 31, 2023.
  • Vaxart reported a net loss of $82.5 million for the full year 2023, compared to $107.8 million for the full year 2022.
  • The Vaxart senior management team will host a conference call to discuss the business update and financial results for the full year 2023 today, beginning at 4:30 p.m.

Allakos Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results

Retrieved on: 
Thursday, March 14, 2024
Research, Atopic dermatitis, PD, Inflammation, Patient, SAN, American Academy, Allergy, Investment, Antibody, Pharmacokinetics, SAD, AAAAI, Annual general meeting, Pharmaceutical industry

Research and development expenses were $53.8 million in the fourth quarter of 2023 compared to $35.4 million in the fourth quarter of 2022, an increase of $18.4 million.

Key Points: 
  • Research and development expenses were $53.8 million in the fourth quarter of 2023 compared to $35.4 million in the fourth quarter of 2022, an increase of $18.4 million.
  • Allakos reported a net loss of $62.6 million in the fourth quarter of 2023 compared to $43.0 million in the fourth quarter of 2022.
  • Net loss per basic and diluted share was $0.71 for the fourth quarter of 2023 compared to $0.50 in the fourth quarter of 2022.
  • Allakos ended the fourth quarter of 2023 with $170.8 million in cash, cash equivalents and investments resulting in a net decrease in cash, cash equivalents and investments of $23.1 million during the fourth quarter of 2023.

PDS Biotech Announces Publication of Preclinical Research and Grant of U.S. Composition of Matter Patent for Infectimune®

Retrieved on: 
Wednesday, March 13, 2024
CD4, PDSB, Infection, Patent, Influenza, Research, Virus, Biotechnology, Antibody, Intellectual property, Use, Viral, Vaccine

PRINCETON, N.J., March 13, 2024 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or “the Company”), a clinical-stage immunotherapy company developing a growing pipeline of targeted cancer immunotherapies and infectious disease vaccines based on the Company’s proprietary T cell-activating platforms, today announced the publication of preclinical research and a patent granted by the United States Patent and Trademark Office (USPTO) that strengthen the foundation of the Company’s infectious disease vaccine platform Infectimune®.

Key Points: 
  • The research concluded that Infectimune® is a leading candidate for use in the next generation of preventive vaccines that may provide more effective and broader protection than current vaccines allow.
  • Infectimune® is being used in PDS0202, the Company’s universal influenza vaccine intended to provide broad protection against multiple flu strains.
  • The patent protects compositions containing the Infectimune® platform and influenza antigens and methods of using the Infectimune® platform with pathogenic antigens generally.
  • “Possessing multiple layers of intellectual property for our assets is an important value driver for PDS Biotech and is a key component of our business strategy.”

Antibody Solutions Secures Grant for Challenging Diagnostic Initiative

Retrieved on: 
Thursday, April 4, 2024
Science, Biotechnology, Research, Pharmaceutical, Health, Medical Devices, Infectious Diseases, Genetics, LDH, Infection, Bill, RDT, Risk, Public, NGS, Antibody Solutions, Doctor of Philosophy, LMIC, Biology, Malaria, Antibody, Melinda French Gates, Vaccine

Antibody Solutions, a leading provider of fit-for-purpose antibody discovery services, announced today that it received a 15-month grant for nearly $1.2 million from the Bill & Melinda Gates Foundation to develop reagents for highly-specified rapid diagnostic tests (RDT) to detect malaria.

Key Points: 
  • Antibody Solutions, a leading provider of fit-for-purpose antibody discovery services, announced today that it received a 15-month grant for nearly $1.2 million from the Bill & Melinda Gates Foundation to develop reagents for highly-specified rapid diagnostic tests (RDT) to detect malaria.
  • The end result is that those RDTs are unable to differentiate between different strains of malaria,” explained John Kenney, PhD, co-founder and president of Antibody Solutions.
  • ”
    Antibody Solutions has already begun work to identify these new antibody reagents by harnessing Cellestive, its antibody discovery platform, that includes multiple discovery pathways such as hybridoma library, primary B-cell screening, and guided next-generation sequencing (NGS).
  • The grant from the foundation will also allow Antibody Solutions to work with industry experts in both public health and the development and deployment of healthcare solutions in low- and middle-income (LMIC) settings, ensuring that these reagents will be widely available.